atorvastatin has been researched along with Insulin Sensitivity in 91 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 29 (31.87) | 29.6817 |
| 2010's | 48 (52.75) | 24.3611 |
| 2020's | 14 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Bao, L; Chen, B; Han, J; Liu, H; Luo, H; Ma, K; Ren, J; Wang, K; Zhang, J | 1 |
| Jameshorani, M; Mellati, AA; Mousavi, SN; Rahimian, A; Rostamkhani, H; Tabaei, BS | 1 |
| Kowalcze, K; Krysiak, R; Okopień, B | 4 |
| Al-Okbi, SY; Ali, O; Aly, AS; Elbakry, HFH; Esmail, RSH; Refaat, D | 1 |
| Di Mauro, S; Di Pino, A; Filippello, A; Marchisello, S; Piro, S; Purrello, F; Rabuazzo, AM; Scamporrino, A; Scicali, R; Urbano, F | 1 |
| Chatsudthipong, V; Cherngwelling, R; Jaikumkao, K; Lungkaphin, A; Pengrattanachot, N; Pongchaidecha, A; Swe, MT; Thongnak, L | 1 |
| Chatsudthipong, V; Kongkaew, A; Lungkaphin, A; Thongnak, L | 1 |
| Barra, NG; Henriksbo, BD; Phulka, JS; Schertzer, JD; Tamrakar, AK | 1 |
| Amput, P; Arunsak, B; Chattipakorn, N; Chattipakorn, SC; Jaiwongkam, T; Kerdphoo, S; Palee, S; Pratchayasakul, W | 1 |
| Mao, Y; Ning, D; Tang, S; Wang, D; Wang, T; Xiong, T; Yang, X; Zhong, H; Zhu, G | 1 |
| Krysiak, R; Okopień, B; Szkróbka, W | 1 |
| Augustin, S; Barberá, A; Bravo, M; Estrella, F; Genescà, J; Gil, M; Hide, D; Martell, M; Raurell, I; Salcedo, MT | 1 |
| Chen, LL; Zheng, JH | 1 |
| Abbas, F; Abbasi, F; Harris, CS; Harris, V; Kim, SH; Knowles, JW; Lamendola, C; Reaven, GM; Reaven, PD; Snyder, MP; Tripathi, P; Tsai, MS | 1 |
| El-Din Aly El-Waseef, DA; El-Kharashi, OA; Mohamed, DI; Nabih, ES | 1 |
| Takaguri, A | 1 |
| An, L; Lin, Y; Ma, G; Mu, G; Qian, L; Ren, L; Zhu, K | 1 |
| Ashkar, AA; Cavallari, JF; Duggan, BM; Henriksbo, BD; Phulka, J; Schertzer, JD; Stampfli, MR; Tamrakar, AK; Xu, J | 1 |
| Dhull, P; Kumar, KV; Patnaik, SK; Upreti, V | 1 |
| Bloigu, R; Morin-Papunen, L; Piltonen, T; Puukka, K; Puurunen, J; Ruokonen, A; Savolainen, MJ; Tapanainen, JS | 1 |
| Barrett, PH; Chan, DC; Ng, TW; Ooi, EM; Watts, GF | 1 |
| Geddawy, A; Imamura, T; Iwasaki, H; Masada, M; Okamura, T; Shimosato, T; Shinozaki, K; Shintaku, H; Tawa, M; Yoshida, Y | 1 |
| Aslam, M; Bhattacharya, SK; Galav, V; Jafri, AA; Madhu, SV | 1 |
| Goyal, A; Gupta, N; Gupta, YK; Singh, S; Tandon, N | 1 |
| Bento, CF; Fernandes, R; Matafome, P; Pereira, P; Seiça, RM; Sena, CM | 1 |
| Canas, JA; Caulfield, MP; Damaso, LC; Gidding, SS; Hossain, J; Mauras, N; Ross, JL; Sikes, KM; Taboada, MV | 1 |
| Abd Elmaaboud, MA; Albarraq, AA; Kabel, AM | 1 |
| Constantin-Teodosiu, D; Greenhaff, PL; Mallinson, JE; Marimuthu, K; Murton, A; Rennie, MJ; Selby, A; Smith, K | 1 |
| Atarashi, H; Kohashi, K; Kosugi, M; Kusama, Y; Nakagomi, A; Shibui, T; Shimizu, W | 1 |
| Barbarash, O; Belik, E; Dyleva, Y; Gruzdeva, O; Karetnikova, V; Uchasova, E | 1 |
| Ballantyne, CM; Hsueh, WA; Lin, J; Lowe, RS; Rosen, JB; Shah, AK; Tershakovec, AM | 1 |
| Zhao, SP; Zhao, W | 2 |
| Eckard, AR; Longenecker, CT; McComsey, GA | 1 |
| Harada, M; Otsuki, M; Wei, L; Yamamoto, M | 1 |
| Aggarwal, S; Aslam, M; Galav, V; Madhu, SV; Sharma, KK | 1 |
| Chen, H; Kong, J; Li, J; Yang, O | 1 |
| Barwari, T; Bonora, E; Fernández-Hernando, C; Goedeke, L; Hughes, AD; Kaudewitz, D; Kiechl, S; Mayr, M; Moschen, AR; Ramírez, CM; Rotllan, N; Santer, P; Skroblin, P; Tilg, H; Whitehead, M; Willeit, J; Willeit, P; Yin, X; Zampetaki, A | 1 |
| Elmendorf, JS; Horvath, EM; Tackett, L | 1 |
| Amaral, C; Cipriano, A; Crisóstomo, J; Louro, T; Matafome, P; Moedas, AR; Monteiro, P; Nunes, E; Rodrigues, L; Seiça, R | 1 |
| Atkin, SL; Coady, AM; Kilpatrick, ES; Sathyapalan, T | 2 |
| Daferera, N; Goulas, A; Hatzitolios, AI; Kokkas, V; Kosmidou, M; Molyva, D; Raikos, N; Savopoulos, C | 1 |
| Antonini, R; Arca, M; Baroni, MG; Cambuli, VM; Campagna, F; Filippi, E; Montali, A; Quagliarini, F; Romeo, S; Sentinelli, F | 1 |
| Favaro, RR; Furuya, DT; Machado, UF; Martins, JO; Poletto, AC; Zorn, TM | 1 |
| Huan, Y; Huang, H; Shen, ZF; Song, GM; Sun, SJ; Zhang, N | 1 |
| Cengiz, SD; Dünder, I; Kaya, C; Pabuccu, R | 1 |
| Han, SH; Kim, SJ; Koh, KK; Lee, Y; Quon, MJ; Shin, EK | 1 |
| Hoenig, MR; Sellke, FW | 1 |
| Bando, YK; Monji, A; Morimoto, Y; Murohara, T; Shigeta, T | 1 |
| Koh, KK; Quon, MJ; Sakuma, I | 1 |
| Byrne, CD; Chipperfield, AJ; Clough, GF; Gamble, J; Krentz, AJ; L'Esperance, V; Turzyniecka, M; Walter, L | 1 |
| Amaral, C; Cipriano, A; Crisóstomo, J; Louro, T; Matafome, P; Monteiro, P; Nunes, E; Rodrigues, L; Seiça, R | 1 |
| Bonner Freeman, A; Brouwers, MC; Konrad, RJ; Lu, A; Schaper, NC; Stehouwer, CD; Troutt, JS; van Greevenbroek, MM | 1 |
| Anagnostis, P; Athyros, VG; Karagiannis, A; Mikhailidis, DP | 1 |
| Barthwal, MK; Dikshit, M; Jain, M; Jyoti, A; Keshari, RS; Khanna, V; Prakash, P; Singh, V | 1 |
| Barter, PJ; Boekholdt, SM; Breazna, A; Kastelein, JJ; Rye, KA; Tardif, JC; Waters, DD | 1 |
| Atanassova, P; Bełtowski, J; Chaldakov, GN; Jamroz-Wiśniewska, A; Kula, W; Rusek, M | 1 |
| Chayama, K; Hyogo, H; Ishitobi, T; Kimura, Y; Maeda, S; Yamagishi, S | 1 |
| El-Bassossy, HM; El-Nagar, M; Mahmoud, MF | 1 |
| El-Moselhy, MA; Heeba, GH; Mourad, AA; Taye, A | 1 |
| Atkin, SL; Coady, AM; Kilpatrick, ES; Sathyapalan, T; Shepherd, J | 1 |
| Buldak, L; Dulawa-Buldak, A; Labuzek, K; Okopien, B | 1 |
| Chen, P; Deng, X; Xia, K; Yang, T; Zhao, Z | 1 |
| Barrett, PH; Beilin, LJ; Chan, DC; Mori, TA; Redgrave, TG; Watts, GF | 1 |
| Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Rinaldi, A; Zoppi, A | 1 |
| Hitsumoto, T; Iizuka, T; Nakamura, K; Noike, H; Ohsawa, H; Sakurai, T; Satoh, S; Shimizu, K; Shirai, K; Sugiyama, Y; Takahashi, M; Watanabe, H | 1 |
| Ishii, T; Kaneki, M; Miyauchi, A; Nagakura, C; Sakurai, S; Tsujibayashi, T; Yoshitomi, Y | 1 |
| Fushimi, H | 1 |
| Kakuta, H; Kihara, R; Shimano, H; Suzuki, M; Tada-Iida, K; Takahashi, A; Yamada, N; Yokoo, T | 1 |
| Moreno Sánchez, D | 1 |
| Fantus, IG; Lewis, GF; Stavar, L; Szeto, L; Uffelman, K; Wang, CH; Wong, V | 1 |
| Dohi, Y; Ohashi, M; Sato, K; Sugiyama, M; Takase, H; Ueda, R | 1 |
| Ichihara, K; Kanda, M; Kasai, T; Keimatsu, N; Satoh, K; Sun, F; Takaguri, A | 1 |
| Geiss, HC; Huptas, S; Otto, C; Parhofer, KG | 1 |
| Barrett, PH; Chan, DC; Nguyen, MN; Watts, GF | 1 |
| Ciccarelli, L; Corradi, L; Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Preti, P; Zoppi, A | 1 |
| Chen, Y; Kohno, M; Kosaka, H; Mizukawa, M; Ohmori, K; Shinomiya, K; Yoshida, J; Zeng, Y; Zhang, L | 1 |
| Bajo, MA; del Peso, G; Díez, JJ; Estrada, PN; Fernández-Reyes, MJ; Grande, C; Iglesias, P; Sánchez Hernández, R; Selgas, R | 1 |
| Nesto, RW; Singh, PP | 1 |
| Janíková, L; Stanková, B; Stopka, P; Tvrzická, E; Vareka, T; Vecka, M; Zahin, M; Zák, A; Zeman, M | 1 |
| Fasshauer, M; Klein, J; Mäuser, W; Meier, B; Perwitz, N | 1 |
| Chan, D; Dogra, G; Irish, A; Watts, G | 1 |
| Adamidou, A; Giannopoulos, S; Hatzitolios, AI; Kosmidou, MS; Milionis, HJ; Parharidis, G; Raikos, N | 1 |
| Chu, CH; Chuang, MJ; Lam, HC; Lee, JK; Lu, CC; Sun, CC; Wang, MC; Wei, MC | 1 |
| Barbagallo, M; Barbieri, M; Giordano, M; Paolisso, G; Petrella, G; Ragno, E; Varricchio, M | 1 |
| Adeli, K; Cheung, RC; Parris, W; Pontrelli, L | 1 |
| Adeli, K; Cheung, RC; Mangaloglu, L; Pontrelli, L; Taghibiglou, C; Van Iderstine, SC | 1 |
6 review(s) available for atorvastatin and Insulin Sensitivity
| Article | Year |
|---|---|
Effects of atorvastatin on the insulin resistance in women of polycystic ovary syndrome: A systematic review and meta-analysis.
Topics: Adolescent; Adult; Atorvastatin; Blood Glucose; Body Mass Index; Fasting; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; Treatment Outcome; Young Adult | 2021 |
[Elucidation of a New Mechanism of Onset of Insulin Resistance: Effects of Statins and Tumor Necrosis Factor-α on Insulin Signal Transduction].
Topics: Adipocytes; AMP-Activated Protein Kinases; Animals; Atorvastatin; Diabetes Mellitus; Dual-Specificity Phosphatases; Extracellular Signal-Regulated MAP Kinases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; JNK Mitogen-Activated Protein Kinases; Mice; Mitogen-Activated Protein Kinase Phosphatases; Phosphorylation; rho-Associated Kinases; rhoA GTP-Binding Protein; Serine; Signal Transduction; Tumor Necrosis Factor-alpha; Tyrosine | 2018 |
Statins to improve cardiovascular outcomes in treated HIV infection.
Topics: Atorvastatin; Carotid Intima-Media Thickness; Coronary Disease; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Practice Guidelines as Topic; Practice Patterns, Physicians'; Precision Medicine; Primary Prevention; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Treatment Outcome; United States | 2016 |
Differential metabolic effects of distinct statins.
Topics: Adiponectin; Animals; Atorvastatin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fluorobenzenes; Heptanoic Acids; Homeostasis; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Mice; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
[Treatment of cerebral infarction patients with IGT].
Topics: Antidepressive Agents; Antipyrine; Atorvastatin; Cerebral Infarction; Edaravone; Free Radical Scavengers; Glucose Intolerance; Heptanoic Acids; Humans; Hyperglycemia; Hypertension; Hypertriglyceridemia; Insulin Resistance; Pyrroles; Secondary Prevention; Thrombolytic Therapy | 2005 |
[Medical management of primary nonalcoholic fatty liver disease].
Topics: Anti-Obesity Agents; Anticholesteremic Agents; Atorvastatin; Chromans; Diabetes Mellitus, Type 2; Fatty Liver; Heptanoic Acids; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Metabolic Syndrome; Metformin; Obesity; Orlistat; Prevalence; Pyrroles; Rosiglitazone; Thiazolidinediones; Troglitazone | 2005 |
29 trial(s) available for atorvastatin and Insulin Sensitivity
| Article | Year |
|---|---|
Co-Administration of Vitamin E and Atorvastatin Improves Insulin Sensitivity and Peroxisome Proliferator-Activated Receptor-γ Expression in Type 2 Diabetic Patients: A Randomized Double-Blind Clinical Trial.
Topics: Atorvastatin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Insulin Resistance; Leukocytes, Mononuclear; PPAR gamma; Vitamin E | 2022 |
Statins Are Associated With Increased Insulin Resistance and Secretion.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Blood Glucose; Diabetes Mellitus; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Lipids; Male; Middle Aged; Prospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2021 |
Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adult; Androgen Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Body Mass Index; Double-Blind Method; Female; Follow-Up Studies; Glucose Intolerance; Glucose Tolerance Test; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperandrogenism; Hyperinsulinism; Hyperlipidemias; Insulin Resistance; Insulin-Secreting Cells; Middle Aged; Overweight; Polycystic Ovary Syndrome; Pyrroles | 2013 |
Atorvastatin plus omega-3 fatty acid ethyl ester decreases very-low-density lipoprotein triglyceride production in insulin resistant obese men.
Topics: Anticholesteremic Agents; Apolipoprotein B-100; Atorvastatin; Docosahexaenoic Acids; Drug Combinations; Drug Therapy, Combination; Dyslipidemias; Eicosapentaenoic Acid; Heptanoic Acids; Humans; Insulin Resistance; Lipoproteins, VLDL; Male; Middle Aged; Obesity; Pyrroles; Treatment Outcome; Triglycerides | 2014 |
Effect of atorvastatin on pancreatic Beta-cell function and insulin resistance in type 2 diabetes mellitus patients: a randomized pilot study.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heptanoic Acids; Humans; Insulin; Insulin Resistance; Insulin-Secreting Cells; Lipids; Male; Middle Aged; Pilot Projects; Pyrroles; Quality of Life | 2014 |
A randomized, double blind, placebo-controlled pilot trial of the safety and efficacy of atorvastatin in children with elevated low-density lipoprotein cholesterol (LDL-C) and type 1 diabetes.
Topics: Adolescent; Atorvastatin; Child; Cholesterol, LDL; Combined Modality Therapy; Diabetes Mellitus, Type 1; Diet, Diabetic; Diet, Fat-Restricted; Double-Blind Method; Drug Monitoring; Exercise; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Pilot Projects; Pyrroles | 2015 |
Differential Effects of Atorvastatin and Pitavastatin on Inflammation, Insulin Resistance, and the Carotid Intima-Media Thickness in Patients with Dyslipidemia.
Topics: Aged; Atorvastatin; Carotid Artery Diseases; Carotid Intima-Media Thickness; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Insulin Resistance; Male; Prognosis; Prospective Studies; Quinolines | 2015 |
Dose-dependent effects of atorvastatin on myocardial infarction.
Topics: Adipokines; Atorvastatin; Biomarkers; Blood Glucose; Dose-Response Relationship, Drug; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Lipids; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Risk Factors; Russia; Secondary Prevention; Time Factors; Treatment Outcome | 2015 |
Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Blood Pressure; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Double-Blind Method; Ezetimibe; Female; Humans; Hypercholesterolemia; Insulin Resistance; Lipoproteins, HDL; Male; Metabolic Syndrome; Middle Aged; Obesity, Abdominal; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides | 2015 |
The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study.
Topics: Adult; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Polycystic Ovary Syndrome; Pyrroles; Testosterone | 2009 |
Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS).
Topics: Adult; Atorvastatin; C-Reactive Protein; Drug Synergism; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Metformin; Polycystic Ovary Syndrome; Pyrroles; Testosterone | 2010 |
Comparison of the effects of atorvastatin and simvastatin in women with polycystic ovary syndrome: A prospective, randomized study.
Topics: Adult; Atorvastatin; C-Reactive Protein; Fasting; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperandrogenism; Inflammation; Insulin; Insulin Resistance; Luteinizing Hormone; Oxidative Stress; Polycystic Ovary Syndrome; Prospective Studies; Pyrroles; Simvastatin; Testosterone; Young Adult | 2010 |
Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients.
Topics: Adult; Aged; Atorvastatin; Blood Glucose; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin; Insulin Resistance; Male; Middle Aged; Pyrroles; Treatment Outcome | 2010 |
Functional dilator capacity is independently associated with insulin sensitivity and age in central obesity and is not improved by high dose statin treatment.
Topics: Acute Disease; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Flow Velocity; Female; Heptanoic Acids; Humans; Hyperemia; Hyperinsulinism; Insulin Resistance; Male; Microcirculation; Middle Aged; Obesity, Abdominal; Pyrroles; Risk Factors; Vasodilation | 2011 |
Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Glycated Hemoglobin; Heptanoic Acids; Homeostasis; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines | 2011 |
Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome.
Topics: Adult; Atorvastatin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin Resistance; Malondialdehyde; Metformin; Oxidative Stress; Polycystic Ovary Syndrome; Pyrroles; Treatment Outcome | 2012 |
Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose.
Topics: Adipokines; Adiponectin; Adult; Aged; Analysis of Variance; Atorvastatin; Biomarkers; Blood Glucose; Cytokines; Drug Therapy, Combination; Female; Fenofibrate; Glucose Metabolism Disorders; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Inflammation Mediators; Insulin; Insulin Resistance; Interleukin-6; Leptin; Lipids; Male; Middle Aged; Poland; Pyrroles; Resistin; Risk Reduction Behavior; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2012 |
Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia.
Topics: Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Fasting; Fatty Acids, Nonesterified; Fish Oils; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Insulin; Insulin Resistance; Kinetics; Male; Middle Aged; Obesity; Placebos; Pyrroles | 2002 |
Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance.
Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Drug Therapy, Combination; Female; Fibrinolysis; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Insulin Resistance; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Pyrroles; Tissue Plasminogen Activator | 2004 |
Relationship between insulin resistance and effect of atorvastatin in non-diabetic subjects.
Topics: Aged; Atorvastatin; Cholesterol, HDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Insulin Resistance; Male; Middle Aged; Pyrroles | 2005 |
Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome.
Topics: Adult; Atorvastatin; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Male; Metabolic Syndrome; Pyrroles; Treatment Outcome | 2006 |
Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity.
Topics: Abdominal Fat; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoprotein A-II; Atorvastatin; Dietary Supplements; Double-Blind Method; Drug Therapy, Combination; Fatty Acids, Omega-3; Fish Oils; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hyperlipidemias; Insulin Resistance; Kinetics; Lipoproteins, HDL; Male; Middle Aged; Obesity; Placebos; Pyrroles; Treatment Outcome | 2006 |
Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients.
Topics: Adult; Aged; Amlodipine; Atorvastatin; Biomarkers; Blood Glucose; Body Mass Index; Calcium Channel Blockers; Cholesterol; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Inflammation; Insulin Resistance; Interleukin-6; Male; Middle Aged; Obesity; Pyrroles; Tablets; Tumor Necrosis Factor-alpha | 2006 |
[Oxidation stress, insulin resistance and endothelial dysfunction during the treatment of hyperlipidaemia].
Topics: Adult; Aged; Atorvastatin; Diabetes Mellitus, Type 2; Endothelium, Vascular; Fatty Acids, Omega-3; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Male; Middle Aged; Oxidative Stress; Pyrroles; Simvastatin | 2006 |
A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD.
Topics: Adult; Aged; Atorvastatin; Brachial Artery; Double-Blind Method; Elasticity; Endothelium, Vascular; Female; Gemfibrozil; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Insulin Resistance; Kidney Failure, Chronic; Male; Middle Aged; Pyrroles; Treatment Outcome | 2007 |
Effects of atorvastatin on red-blood cell Na(+)/Li(+) countertransport in hyperlipidemic patients with and without hypertension.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Biological Transport; Blood Pressure; Cholesterol; Dose-Response Relationship, Drug; Erythrocytes; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Insulin Resistance; Linear Models; Lithium; Male; Middle Aged; Pyrroles; Sodium; Triglycerides | 2008 |
Atorvastatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic Type 2 diabetes.
Topics: Adiponectin; Aged; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hyperlipidemias; Insulin Resistance; Leptin; Male; Middle Aged; Pyrroles | 2008 |
Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients.
Topics: Aged; Atorvastatin; Calorimetry, Indirect; Carbon Dioxide; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Energy Metabolism; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Male; Oxygen Consumption; Pyrroles; Simvastatin; Single-Blind Method; Triglycerides | 2000 |
Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes.
Topics: Apolipoproteins B; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Insulin Resistance; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Particle Size; Peptide Fragments; Pyrroles | 2002 |
56 other study(ies) available for atorvastatin and Insulin Sensitivity
| Article | Year |
|---|---|
A novel class of α-glucosidase and HMG-CoA reductase inhibitors from Ganoderma leucocontextum and the anti-diabetic properties of ganomycin I in KK-A
Topics: Adipose Tissue; Alanine Transaminase; alpha-Glucosidases; Animals; Aspartate Aminotransferases; Blood Glucose; Body Weight; Female; Ganoderma; Glycogen; Glycoside Hydrolase Inhibitors; Hydroquinones; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin Resistance; Kinetics; Liver; Male; Mice; Molecular Docking Simulation; Protein Conformation | 2017 |
Thyroid Antibody Titers and Hypothalamic-Pituitary-Thyroid Axis Activity in Levothyroxine-Treated Women With Autoimmune Subclinical Hypothyroidism Receiving Atorvastatin or Metformin.
Topics: Atorvastatin; C-Reactive Protein; Female; Hashimoto Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypothyroidism; Inflammation; Insulin Resistance; Metformin; Thyroid Hormones; Thyrotropin; Thyroxine | 2022 |
Cabergoline-Induced Hypoprolactinemia May Attenuate Cardiometabolic Effects of Atorvastatin: A Pilot Study.
Topics: Androgens; Atorvastatin; C-Reactive Protein; Cabergoline; Cardiovascular Diseases; Female; Fibrinogen; Homocysteine; Humans; Insulin Resistance; Pilot Projects; Prolactin; Risk Factors; Uric Acid | 2022 |
Management of metabolic syndrome by nutraceuticals prepared from chitosan and ferulic acid with or without beta-sitosterol and their nanoforms.
Topics: Animals; Atorvastatin; Chitosan; Diet, High-Fat; Dietary Supplements; Fructose; Insulin Resistance; Metabolic Syndrome; Rats | 2023 |
The Impact of Atorvastatin on Cardiometabolic Risk Factors in Sisters of Women with Polycystic Ovary Syndrome.
Topics: Androgens; Atorvastatin; C-Reactive Protein; Cardiometabolic Risk Factors; Cardiovascular Diseases; Female; Fibrinogen; Humans; Insulin Resistance; Polycystic Ovary Syndrome; Risk Factors; Siblings; Testosterone; Uric Acid | 2023 |
Impact of Macroprolactinemia on Cardiometabolic Effects of Atorvastatin in Women With Hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Hyperprolactinemia; Incidence; Insulin Resistance; Middle Aged; Poland; Prolactin; Risk Factors | 2019 |
Impaired glucagon suppression and reduced insulin sensitivity in subjects with prediabetes undergoing atorvastatin therapy.
Topics: Adult; Aged; Atorvastatin; Blood Glucose; Blotting, Western; Cell Line; Female; Glucagon; Glucose Tolerance Test; Humans; Immunoprecipitation; Insulin Resistance; Male; Middle Aged; Multivariate Analysis; Prediabetic State | 2019 |
Atorvastatin attenuates obese-induced kidney injury and impaired renal organic anion transporter 3 function through inhibition of oxidative stress and inflammation.
Topics: Acute Kidney Injury; Animals; Antioxidants; Atorvastatin; Diet, High-Fat; Humans; Inflammation; Insulin; Insulin Resistance; Kidney; Lipid Metabolism; Obesity; Organic Anion Transporters, Sodium-Independent; Oxidative Stress; Rats; Rats, Wistar | 2020 |
Effects of dapagliflozin and statins attenuate renal injury and liver steatosis in high-fat/high-fructose diet-induced insulin resistant rats.
Topics: Acute Kidney Injury; Animals; Atorvastatin; Benzhydryl Compounds; Blotting, Western; Dietary Carbohydrates; Dietary Fats; Drug Therapy, Combination; Fatty Liver; Fructose; Glucosides; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Male; Rats; Rats, Wistar | 2020 |
Statins activate the NLRP3 inflammasome and impair insulin signaling via p38 and mTOR.
Topics: Adipose Tissue; Animals; Atorvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammasomes; Insulin; Insulin Resistance; Interleukin-1beta; MAP Kinase Kinase 4; Mice; Mice, Knockout; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; NLR Family, Pyrin Domain-Containing 3 Protein; p38 Mitogen-Activated Protein Kinases; PTEN Phosphohydrolase; TOR Serine-Threonine Kinases | 2020 |
PCSK9 inhibitor effectively attenuates cardiometabolic impairment in obese-insulin resistant rats.
Topics: Animals; Apoptosis; Atorvastatin; Calcium Signaling; Diet, High-Fat; Disease Models, Animal; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Metabolic Syndrome; Mitochondria, Heart; Myocytes, Cardiac; Obesity; PCSK9 Inhibitors; Proprotein Convertase 9; Rats, Wistar; Recovery of Function; Serine Proteinase Inhibitors; Ventricular Function, Left | 2020 |
Long-term atorvastatin or the combination of atorvastatin and nicotinamide ameliorate insulin resistance and left ventricular diastolic dysfunction in a murine model of obesity.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Diet, High-Fat; Drug Therapy, Combination; Insulin; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Niacinamide; Obesity; Random Allocation; Ventricular Dysfunction, Left; Vitamin B Complex | 2020 |
The impact of atorvastatin on cardiometabolic risk factors in brothers of women with polycystic ovary syndrome.
Topics: Adult; Aged; Androgens; Anticholesteremic Agents; Atorvastatin; Blood Glucose; C-Reactive Protein; Cardiometabolic Risk Factors; Female; Fibrinogen; Homocysteine; Humans; Hydroxycholecalciferols; Insulin Resistance; Lipids; Male; Middle Aged; Polycystic Ovary Syndrome; Risk Factors; Testosterone; Uric Acid | 2021 |
Synergic effect of atorvastatin and ambrisentan on sinusoidal and hemodynamic alterations in a rat model of NASH.
Topics: Alanine Transaminase; Animals; Atorvastatin; Biomarkers; Collagen; Disease Models, Animal; Drug Synergism; Endothelial Cells; Endothelin-1; Enzyme Activation; Hemodynamics; Hepatic Stellate Cells; Insulin Resistance; Liver; Liver Cirrhosis; Nitric Oxide Synthase Type III; Non-alcoholic Fatty Liver Disease; Phenylpropionates; Pyridazines; Weight Gain | 2021 |
Targeting NLRP3 inflammasome via acetylsalicylic acid: Role in suppressing hepatic dysfunction and insulin resistance induced by atorvastatin in naïve versus alcoholic liver in rats.
Topics: Alcoholism; Animals; Aspirin; Atorvastatin; Bile Acids and Salts; Caspase 8; Hepatocytes; Inflammasomes; Insulin Resistance; Liver; Liver Function Tests; Male; NLR Family, Pyrin Domain-Containing 3 Protein; Perfusion; Rats, Wistar; Staining and Labeling; Sulfobromophthalein | 2018 |
Pioglitazone Ameliorates Atorvastatin-Induced Islet Cell Dysfunction through Activation of FFA1 in INS-1 Cells.
Topics: Animals; Atorvastatin; Basic Helix-Loop-Helix Transcription Factors; Cell Line; Homeodomain Proteins; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Islets of Langerhans; Nerve Tissue Proteins; Pioglitazone; Rats; Receptors, G-Protein-Coupled; Trans-Activators | 2019 |
Statins Promote Interleukin-1β-Dependent Adipocyte Insulin Resistance Through Lower Prenylation, Not Cholesterol.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; Animals; Atorvastatin; Caspase 1; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammasomes; Insulin; Insulin Resistance; Interleukin-1beta; Lipogenesis; Male; Mevalonic Acid; Mice; Mice, Mutant Strains; Prenylation | 2019 |
An unusual cause of delayed puberty: Berardinelli- Seip syndrome.
Topics: Administration, Cutaneous; Adolescent; Atorvastatin; Combined Modality Therapy; Diet, Fat-Restricted; Drug Therapy, Combination; Estrogens; Exercise Therapy; Female; Fenofibrate; Fish Oils; Heptanoic Acids; Humans; Hypertension, Portal; Hypertriglyceridemia; Insulin; Insulin Resistance; Lipodystrophy, Congenital Generalized; Pioglitazone; Propranolol; Puberty, Delayed; Pyrroles; Thiazolidinediones; Treatment Outcome | 2012 |
Effects of atorvastatin, amlodipine, and their combination on vascular dysfunction in insulin-resistant rats.
Topics: Amlodipine; Animals; Atorvastatin; Biopterins; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Disease Models, Animal; Drug Therapy, Combination; Endothelium, Vascular; Fructose; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Pyrroles; Rats; Rats, Sprague-Dawley; Superoxides; Vasoconstriction; Vasodilation | 2014 |
Atorvastatin prevents type 2 diabetes mellitus--an experimental study.
Topics: Animals; Atorvastatin; Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Lipid Metabolism; Male; Pyrroles; Rats; Rats, Wistar; Triglycerides | 2014 |
Atorvastatin-mediated protection of the retina in a model of diabetes with hyperlipidemia.
Topics: Animals; Antioxidants; Atorvastatin; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Diet, Atherogenic; Heptanoic Acids; Hyperlipidemias; Insulin Resistance; Lipid Metabolism; Male; Oxidative Stress; Proteasome Endopeptidase Complex; Pyrroles; Rats; Reactive Oxygen Species; Retina; Ubiquitin | 2014 |
Ameliorative potential of omega 3 fatty acids and HMG-CoA reductase inhibitors on experimentally-induced non-alcoholic steatohepatitis.
Topics: Animals; Atorvastatin; Body Weight; Cytokines; Diet, High-Fat; Disease Models, Animal; Fatty Acids, Omega-3; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Insulin Resistance; Lipids; Liver; Male; Non-alcoholic Fatty Liver Disease; Rats, Wistar; Sucrose | 2015 |
Statin myalgia is not associated with reduced muscle strength, mass or protein turnover in older male volunteers, but is allied with a slowing of time to peak power output, insulin resistance and differential muscle mRNA expression.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Humans; Insulin Resistance; Male; Muscle Contraction; Muscle Proteins; Muscle Strength; Muscle Weakness; Reaction Time; RNA, Messenger; Simvastatin | 2015 |
Atorvastatin might inhibit insulin resistance induced by insulin through the triglyceride-lowering role of Apolipoprotein AV.
Topics: Anticholesteremic Agents; Apolipoprotein A-V; Apolipoproteins A; Atorvastatin; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Hep G2 Cells; Humans; Insulin; Insulin Resistance; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Triglycerides | 2015 |
Different effects of statins on induction of diabetes mellitus: an experimental study.
Topics: Atorvastatin; Cell Cycle; Cell Survival; Cells, Cultured; Diabetes Mellitus; Dose-Response Relationship, Drug; Glucose; Humans; Insulin; Insulin Resistance; Insulin-Secreting Cells; Muscle, Skeletal; Pravastatin; Quinolines; Rosuvastatin Calcium; Signal Transduction; Structure-Activity Relationship | 2015 |
Treatment with atorvastatin attenuates progression of insulin resistance and pancreatic fibrosis in the Otsuka Long-Evans Tokushima fatty rats.
Topics: Animals; Antioxidants; Apoptosis; Atorvastatin; Body Weight; Eating; Fibrosis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Male; Oxidative Stress; Pancreas; Rats; Rats, Inbred OLETF; Transforming Growth Factor beta1 | 2016 |
Postprandial Hypertriglyceridemia Predicts Development of Insulin Resistance Glucose Intolerance and Type 2 Diabetes.
Topics: Animals; Atorvastatin; Blood Glucose; Body Weight; Causality; Diabetes Mellitus, Type 2; Dietary Fats; Dietary Sucrose; Disease Progression; Glucose Intolerance; Glucose Tolerance Test; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypoglycemic Agents; Insulin Resistance; Intra-Abdominal Fat; Lipids; Liver; Male; Pancreas; Pioglitazone; Postprandial Period; Prediabetic State; Random Allocation; Rats; Rats, Wistar; Thiazolidinediones | 2016 |
Atorvastatin ameliorates endothelium-specific insulin resistance induced by high glucose combined with high insulin.
Topics: Atorvastatin; Endothelin-1; Endothelium, Vascular; Enzyme Activation; Gene Expression; Glucose; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; RNA, Messenger; Signal Transduction | 2016 |
Circulating MicroRNA-122 Is Associated With the Risk of New-Onset Metabolic Syndrome and Type 2 Diabetes.
Topics: Adult; Aged; Animals; Antagomirs; Atorvastatin; Blotting, Northern; Carrier Proteins; Complement Factor H; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Glycoproteins; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Insulin Resistance; Lipid Metabolism; Lipoproteins, VLDL; Male; Mass Spectrometry; Metabolic Syndrome; Mice; MicroRNAs; Middle Aged; Multivariate Analysis; Obesity; Oligonucleotides; Prevalence; Prospective Studies; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Serum Albumin; Serum Albumin, Human | 2017 |
A novel membrane-based anti-diabetic action of atorvastatin.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Atorvastatin; Cell Membrane; Cholesterol; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Insulin Resistance; Mice; Picolinic Acids; Pyrroles | 2008 |
A role for atorvastatin and insulin combination in protecting from liver injury in a model of type 2 diabetes with hyperlipidemia.
Topics: Administration, Oral; Animals; Anticholesteremic Agents; Atorvastatin; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Drug Therapy, Combination; Fatty Liver; Heptanoic Acids; Hyperlipidemias; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Insulin Resistance; Lipids; Oxidative Stress; Pyrroles; Rats; Rats, Inbred Strains | 2009 |
An association study between catalase -262C>T gene polymorphism, sodium-lithium countertransport activity, insulin resistance, blood lipid parameters and their response to atorvastatin, in Greek dyslipidaemic patients and normolipidaemic controls.
Topics: Adult; Alleles; Antiporters; Atorvastatin; Case-Control Studies; Catalase; Dyslipidemias; Erythrocytes; Female; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Linear Models; Lipids; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrroles; Retrospective Studies | 2009 |
Serum adiponectin is decreased in patients with familial combined hyperlipidemia and normolipaemic relatives and is influenced by lipid-lowering treatment.
Topics: Adiponectin; Adult; Age Distribution; Atorvastatin; Biomarkers; Cholesterol, HDL; Family; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Insulin Resistance; Male; Middle Aged; Phenotype; Prevalence; Pyrroles; Randomized Controlled Trials as Topic; Waist Circumference; Young Adult | 2009 |
Anti-inflammatory effect of atorvastatin ameliorates insulin resistance in monosodium glutamate-treated obese mice.
Topics: Adipose Tissue, White; Animals; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Blood Glucose; Cytokines; Enzyme-Linked Immunosorbent Assay; Glucose Transporter Type 4; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; I-kappa B Kinase; Immunohistochemistry; Insulin Resistance; Lipids; Male; Mice; Obesity; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA; Sodium Glutamate | 2010 |
Atorvastatin improves insulin sensitivity in mice with obesity induced by monosodium glutamate.
Topics: Adipose Tissue; Administration, Oral; Animals; Atorvastatin; Blood Glucose; Blotting, Western; Disease Models, Animal; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Lipid Metabolism; Mice; Mice, Inbred ICR; Obesity; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sodium Glutamate | 2010 |
Insulin resistance is associated with increased cholesterol synthesis, decreased cholesterol absorption and enhanced lipid response to statin therapy.
Topics: Aged; Atorvastatin; Cholesterol; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Lipids; Male; Metabolic Syndrome; Middle Aged; Pyrroles | 2010 |
Atorvastatin prevents ischemic limb loss in type 2 diabetes: role of p53.
Topics: Animals; Atorvastatin; Blotting, Western; Cells, Cultured; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Extremities; Heart; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Ischemia; Male; Mice; Myoblasts; Peripheral Arterial Disease; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-mdm2; Pyrroles; Tumor Suppressor Protein p53; Ubiquitin; Wound Healing | 2011 |
Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Body Weight; C-Reactive Protein; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Combinations; Fatty Liver; Heptanoic Acids; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Interleukin-6; Liver; Metformin; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Pyrroles; Rats; Rats, Inbred Strains; Tumor Necrosis Factor-alpha | 2011 |
Plasma proprotein convertase subtilisin kexin type 9 is a heritable trait of familial combined hyperlipidaemia.
Topics: Adult; Aged; Apolipoproteins B; Atorvastatin; Body Mass Index; Family Health; Female; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Insulin Resistance; Lipoproteins, VLDL; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Serine Endopeptidases; Sterol Regulatory Element Binding Protein 2 | 2011 |
Impact of statins on glucose metabolism--a matter of debate.
Topics: Atorvastatin; Fluorobenzenes; Glucose; Heptanoic Acids; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2011 |
Atorvastatin protects against ischemia-reperfusion injury in fructose-induced insulin resistant rats.
Topics: Animals; Atorvastatin; Endothelium, Vascular; Fructose; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Male; Nitric Oxide Synthase; Nitrites; Oxidative Stress; Proto-Oncogene Proteins c-akt; Pyrroles; Rats; Rats, Wistar; Reperfusion Injury | 2011 |
Opposite effects of pravastatin and atorvastatin on insulin sensitivity in the rat: role of vitamin D metabolites.
Topics: Adipokines; Adipose Tissue; Animals; Atorvastatin; Biomarkers; Blood Glucose; Calcifediol; Calcitriol; Cholecalciferol; Fasting; Fatty Acids, Nonesterified; Glucose Clamp Technique; Glycerol; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Insulin; Insulin Resistance; Liver; Male; Muscle, Skeletal; Pravastatin; Pyrroles; Rats; Rats, Wistar; Time Factors | 2011 |
Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property.
Topics: Adiponectin; Adult; Alanine Transaminase; Anticholesteremic Agents; Aspartate Aminotransferases; Atorvastatin; Blood Glucose; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Collagen Type IV; Dyslipidemias; Fatty Liver; Female; gamma-Glutamyltransferase; Heptanoic Acids; Humans; Insulin Resistance; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pyrroles; Regression Analysis; Severity of Illness Index; Triglycerides; Tumor Necrosis Factor-alpha | 2012 |
Anti-inflammatory effect of atorvastatin on vascular reactivity and insulin resistance in fructose fed rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta, Thoracic; Atorvastatin; Dietary Sucrose; Fructose; Heptanoic Acids; Insulin Resistance; Male; Pyrroles; Rats; Rats, Wistar; Vascular Diseases | 2012 |
Comparative study between atorvastatin and losartan on high fat diet-induced type 2 diabetes mellitus in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet, High-Fat; Drug Therapy, Combination; Heptanoic Acids; Hypercholesterolemia; Hyperglycemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Losartan; Male; Obesity; Pioglitazone; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2013 |
Atorvastatin modulates the DDAH1/ADMA system in high-fat diet-induced insulin-resistant rats with endothelial dysfunction.
Topics: Amidohydrolases; Animals; Arginine; Atorvastatin; Diet, High-Fat; Endothelial Cells; Endothelium, Vascular; Heptanoic Acids; Insulin; Insulin Resistance; Pyrroles; Rats; Rats, Sprague-Dawley | 2012 |
[A relationship between insulin resistance and reduction in oxidative stress in vivo by atorvastatin].
Topics: Aged; Atorvastatin; Dinoprost; Female; Heptanoic Acids; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin Resistance; Lipids; Male; Middle Aged; Oxidative Stress; Pyrroles | 2004 |
Effects of atorvastatin on glucose metabolism and insulin resistance in KK/Ay mice.
Topics: Animals; Arteriosclerosis; Atorvastatin; Biomarkers; Blood Glucose; Blotting, Northern; CCAAT-Enhancer-Binding Proteins; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Gene Expression Regulation, Enzymologic; Glucose Tolerance Test; Glucose-6-Phosphatase; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Lipids; Male; Mice; Mice, Inbred Strains; Pyrroles; RNA, Messenger; Sterol Regulatory Element Binding Protein 1; Transcription Factors | 2005 |
Atorvastatin induces insulin sensitization in Zucker lean and fatty rats.
Topics: Adipose Tissue; Animals; Atorvastatin; Blotting, Western; Body Weight; Diabetes Mellitus, Type 2; Follow-Up Studies; Glucose; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Male; Muscle, Skeletal; Phosphorylation; Pyrroles; Rats; Rats, Zucker | 2006 |
Effects of atorvastatin on inflammation and oxidative stress.
Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Insulin Resistance; Isoprostanes; Middle Aged; Oxidative Stress; Pyrroles; Tunica Intima | 2005 |
HMG-CoA reductase inhibitors do not improve glucose intolerance in spontaneously diabetic Goto-Kakizaki rats.
Topics: Animals; Atorvastatin; Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Glucose Intolerance; Glucose Tolerance Test; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Male; Pravastatin; Pyrroles; Rats; Rats, Wistar; Simvastatin | 2005 |
Differential impact of atorvastatin vs pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes.
Topics: Adiponectin; Adipose Tissue; Animals; Anticholesteremic Agents; Atorvastatin; Chemokine CCL2; Diabetes Mellitus, Type 2; Disease Models, Animal; Gene Expression Regulation; Glucose; Heptanoic Acids; Hypertriglyceridemia; Insulin Resistance; Leptin; Myocardium; Nitric Oxide; Nitric Oxide Synthase Type III; Pravastatin; Pyrroles; Rats; Rats, Long-Evans; Rats, Mutant Strains; RNA, Messenger; Transforming Growth Factor beta1; Ventricular Dysfunction, Left | 2007 |
[Hypoadiponectinemia: a cardiovascular risk factor in uremia. A view from the evidence].
Topics: Adiponectin; Animals; Atorvastatin; Cardiovascular Diseases; Coronary Restenosis; Disease Models, Animal; Heptanoic Acids; Humans; Insulin Resistance; Kidney Failure, Chronic; Peritoneal Dialysis; PPAR gamma; Prospective Studies; Pyrroles; Rats; Renal Dialysis; Risk Factors; Thiazolidinediones; Uremia | 2006 |
Diabetes and residual risk of coronary heart disease.
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Heptanoic Acids; Humans; Insulin Resistance; Obesity; Pyrroles; Risk Factors; Simvastatin | 2007 |
Direct adipotropic actions of atorvastatin: differentiation state-dependent induction of apoptosis, modulation of endocrine function, and inhibition of glucose uptake.
Topics: Adipocytes, Brown; Adipocytes, White; Animals; Apoptosis; Atorvastatin; CCAAT-Enhancer-Binding Protein-beta; Cell Differentiation; Cell Proliferation; Cell Survival; Cells, Cultured; Endocrine System; Gene Expression Regulation; Glucose; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoblotting; Inflammation Mediators; Insulin Resistance; Ion Channels; Mice; Mitochondrial Proteins; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrroles; Uncoupling Protein 1 | 2007 |
Treatment with atorvastatin ameliorates hepatic very-low-density lipoprotein overproduction in an animal model of insulin resistance, the fructose-fed Syrian golden hamster: evidence that reduced hypertriglyceridemia is accompanied by improved hepatic ins
Topics: Animals; Apolipoproteins B; Atorvastatin; Blood Glucose; Cells, Cultured; Cholesterol; Cricetinae; Disease Models, Animal; Fructose; Hepatocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Insulin Resistance; Kinetics; Lipoproteins, VLDL; Liver; Luminescent Measurements; Mesocricetus; Phosphorylation; Pyrroles; Receptor, Insulin; Triglycerides | 2002 |